
reNEW’s #AnnualReport 2025 is fresh off the press.
The collaborative work among reNEW’s three research nodes in Copenhagen, Leiden, and Melbourne started just over four years ago and is yielding tangible results!
“With a growing portfolio of intellectual property, we are now mapping paths forward for research tools and reagents, hit compounds and screening platforms, as well as cell and gene-edited cell products, said Professor Melissa Little, the CEO of reNEW.
reNEW researchers have over the past four years also delivered 276 peer-reviewed publications, generating more than 3,700 citations, with 65.2% of these in the top 10% of scientific journals.
You can read more about our exciting journey in lnkd.in/echv-M-v
#IntellectualProperty #IP #academicpublishing #journal #Stemcells #stemcellresearch #science #researchexchange #raredisease
@novonordiskfond @UCPH_health

English

















